 Jonathan Kaufman
Concepts (276)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units, Pediatric | 7 | 2020 | 233 | 1.700 |
Why?
| | Cardiac Surgical Procedures | 11 | 2020 | 530 | 1.700 |
Why?
| | Heart Defects, Congenital | 11 | 2020 | 831 | 1.420 |
Why?
| | Multiple Myeloma | 8 | 2024 | 253 | 1.170 |
Why?
| | Hyponatremia | 2 | 2016 | 42 | 0.920 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 13 | 2024 | 1683 | 0.910 |
Why?
| | Postoperative Complications | 9 | 2020 | 2624 | 0.880 |
Why?
| | Quality Improvement | 3 | 2018 | 1152 | 0.870 |
Why?
| | Enteral Nutrition | 7 | 2020 | 200 | 0.730 |
Why?
| | Intensive Care Units | 5 | 2020 | 802 | 0.620 |
Why?
| | Airway Extubation | 1 | 2020 | 57 | 0.620 |
Why?
| | Infant, Newborn | 23 | 2020 | 6046 | 0.610 |
Why?
| | Vascular Access Devices | 1 | 2018 | 26 | 0.570 |
Why?
| | Cardiac Care Facilities | 1 | 2017 | 13 | 0.570 |
Why?
| | Dexamethasone | 9 | 2024 | 377 | 0.550 |
Why?
| | Postoperative Care | 3 | 2014 | 257 | 0.550 |
Why?
| | Heart Diseases | 3 | 2016 | 359 | 0.530 |
Why?
| | Hypernatremia | 1 | 2016 | 8 | 0.530 |
Why?
| | Hypoplastic Left Heart Syndrome | 2 | 2014 | 121 | 0.490 |
Why?
| | Vasodilator Agents | 3 | 2013 | 331 | 0.490 |
Why?
| | Stem Cell Transplantation | 2 | 2022 | 177 | 0.480 |
Why?
| | Boronic Acids | 3 | 2014 | 38 | 0.460 |
Why?
| | Tachycardia | 2 | 2014 | 58 | 0.450 |
Why?
| | Infant | 18 | 2020 | 9442 | 0.440 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 49 | 0.440 |
Why?
| | Blood Chemical Analysis | 1 | 2014 | 99 | 0.440 |
Why?
| | Pyrazines | 3 | 2014 | 91 | 0.430 |
Why?
| | Infant, Premature | 3 | 2020 | 567 | 0.430 |
Why?
| | Parenteral Nutrition | 1 | 2015 | 107 | 0.430 |
Why?
| | Milrinone | 1 | 2013 | 29 | 0.420 |
Why?
| | Norwood Procedures | 1 | 2013 | 29 | 0.420 |
Why?
| | Calcitonin | 1 | 2013 | 27 | 0.420 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2013 | 30 | 0.420 |
Why?
| | Prilocaine | 1 | 2013 | 4 | 0.410 |
Why?
| | Methemoglobinemia | 1 | 2013 | 13 | 0.410 |
Why?
| | Lidocaine | 1 | 2013 | 42 | 0.400 |
Why?
| | Tidal Volume | 1 | 2013 | 86 | 0.400 |
Why?
| | Protein Precursors | 1 | 2013 | 132 | 0.390 |
Why?
| | Anesthetics, Local | 1 | 2013 | 80 | 0.390 |
Why?
| | Masks | 1 | 2013 | 62 | 0.390 |
Why?
| | Critical Illness | 2 | 2016 | 807 | 0.390 |
Why?
| | Thrombosis | 2 | 2018 | 367 | 0.380 |
Why?
| | Nutritional Status | 1 | 2015 | 344 | 0.380 |
Why?
| | Bronchiolitis | 1 | 2013 | 91 | 0.380 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2013 | 82 | 0.380 |
Why?
| | Cardiac Output, Low | 1 | 2012 | 66 | 0.370 |
Why?
| | Cardiotonic Agents | 1 | 2012 | 125 | 0.360 |
Why?
| | Catheter Obstruction | 1 | 2011 | 4 | 0.360 |
Why?
| | Weight Gain | 1 | 2015 | 518 | 0.360 |
Why?
| | C-Reactive Protein | 1 | 2013 | 411 | 0.350 |
Why?
| | Chylothorax | 1 | 2010 | 16 | 0.350 |
Why?
| | Octreotide | 1 | 2010 | 26 | 0.350 |
Why?
| | Length of Stay | 6 | 2018 | 1208 | 0.340 |
Why?
| | Thoracic Surgical Procedures | 1 | 2010 | 73 | 0.320 |
Why?
| | Heart Rate | 1 | 2013 | 823 | 0.320 |
Why?
| | Retrospective Studies | 17 | 2020 | 15564 | 0.320 |
Why?
| | Heparin | 1 | 2011 | 258 | 0.310 |
Why?
| | Catheterization, Central Venous | 1 | 2011 | 111 | 0.310 |
Why?
| | Seizures | 1 | 2013 | 430 | 0.310 |
Why?
| | Bortezomib | 7 | 2024 | 54 | 0.310 |
Why?
| | Abnormalities, Multiple | 1 | 2011 | 189 | 0.310 |
Why?
| | Gastrostomy | 2 | 2020 | 112 | 0.310 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2012 | 292 | 0.310 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 5 | 2013 | 88 | 0.300 |
Why?
| | Lymphoma, Non-Hodgkin | 3 | 2015 | 87 | 0.290 |
Why?
| | Vasculitis | 1 | 2008 | 65 | 0.290 |
Why?
| | Humans | 48 | 2024 | 136783 | 0.290 |
Why?
| | Palliative Care | 1 | 2015 | 743 | 0.290 |
Why?
| | Male | 35 | 2024 | 67361 | 0.280 |
Why?
| | Sepsis | 1 | 2013 | 611 | 0.270 |
Why?
| | Colorado | 5 | 2020 | 4491 | 0.260 |
Why?
| | Female | 33 | 2024 | 72840 | 0.250 |
Why?
| | Antibodies, Monoclonal | 4 | 2024 | 1428 | 0.250 |
Why?
| | Critical Care | 1 | 2011 | 583 | 0.250 |
Why?
| | Respiration, Artificial | 3 | 2020 | 642 | 0.240 |
Why?
| | Incidence | 5 | 2020 | 2788 | 0.220 |
Why?
| | Enterocolitis, Necrotizing | 2 | 2018 | 38 | 0.210 |
Why?
| | Intubation, Intratracheal | 2 | 2020 | 259 | 0.210 |
Why?
| | Biomarkers | 3 | 2016 | 4158 | 0.210 |
Why?
| | Rhabdomyosarcoma | 1 | 2024 | 72 | 0.210 |
Why?
| | Follow-Up Studies | 7 | 2020 | 5115 | 0.210 |
Why?
| | Intubation, Gastrointestinal | 2 | 2020 | 77 | 0.210 |
Why?
| | Child, Preschool | 12 | 2019 | 11069 | 0.200 |
Why?
| | Prospective Studies | 7 | 2018 | 7583 | 0.200 |
Why?
| | Maintenance Chemotherapy | 1 | 2022 | 35 | 0.190 |
Why?
| | Cohort Studies | 5 | 2019 | 5718 | 0.190 |
Why?
| | Child | 12 | 2024 | 21968 | 0.190 |
Why?
| | Time Factors | 8 | 2017 | 6792 | 0.190 |
Why?
| | Disease-Free Survival | 5 | 2022 | 687 | 0.190 |
Why?
| | Acute Kidney Injury | 4 | 2020 | 811 | 0.190 |
Why?
| | Cyclophosphamide | 5 | 2020 | 248 | 0.190 |
Why?
| | Rituximab | 6 | 2015 | 178 | 0.180 |
Why?
| | Drug Administration Schedule | 6 | 2014 | 783 | 0.180 |
Why?
| | Cyanosis | 1 | 2020 | 16 | 0.170 |
Why?
| | Risk Factors | 8 | 2020 | 10331 | 0.170 |
Why?
| | Immunoglobulin Light-chain Amyloidosis | 1 | 2020 | 7 | 0.170 |
Why?
| | Fundoplication | 1 | 2020 | 53 | 0.170 |
Why?
| | Analysis of Variance | 2 | 2013 | 1318 | 0.170 |
Why?
| | Smoldering Multiple Myeloma | 1 | 2019 | 7 | 0.160 |
Why?
| | Clinical Trials as Topic | 1 | 2024 | 1043 | 0.160 |
Why?
| | Calcaneus | 1 | 2019 | 31 | 0.160 |
Why?
| | Lymphoma, B-Cell | 2 | 2012 | 105 | 0.150 |
Why?
| | Ketorolac | 1 | 2018 | 20 | 0.150 |
Why?
| | Treatment Outcome | 10 | 2020 | 10764 | 0.150 |
Why?
| | Platelet Aggregation | 1 | 2018 | 100 | 0.150 |
Why?
| | Gastroesophageal Reflux | 1 | 2020 | 234 | 0.140 |
Why?
| | Catheters, Indwelling | 1 | 2018 | 83 | 0.140 |
Why?
| | Urine Specimen Collection | 1 | 2017 | 2 | 0.140 |
Why?
| | Combined Modality Therapy | 2 | 2010 | 1235 | 0.140 |
Why?
| | Morphine | 1 | 2018 | 160 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2014 | 2045 | 0.130 |
Why?
| | Diuretics | 1 | 2016 | 74 | 0.130 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2016 | 56 | 0.120 |
Why?
| | Lymphoma, Follicular | 2 | 2015 | 40 | 0.120 |
Why?
| | Sodium | 1 | 2016 | 214 | 0.120 |
Why?
| | Pain, Postoperative | 1 | 2018 | 267 | 0.120 |
Why?
| | Bone Density | 1 | 2019 | 487 | 0.120 |
Why?
| | Urinary Tract Infections | 1 | 2017 | 168 | 0.120 |
Why?
| | Prognosis | 5 | 2018 | 4018 | 0.120 |
Why?
| | Logistic Models | 4 | 2014 | 2060 | 0.120 |
Why?
| | Quality of Life | 2 | 2024 | 2868 | 0.110 |
Why?
| | Thalidomide | 2 | 2015 | 40 | 0.110 |
Why?
| | Gestational Age | 2 | 2020 | 902 | 0.110 |
Why?
| | Transplantation, Autologous | 3 | 2022 | 237 | 0.110 |
Why?
| | Hypertension, Pulmonary | 1 | 2005 | 1902 | 0.110 |
Why?
| | Aged | 11 | 2024 | 23729 | 0.110 |
Why?
| | Heart | 1 | 2018 | 656 | 0.110 |
Why?
| | Remission Induction | 2 | 2014 | 287 | 0.110 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2013 | 39 | 0.100 |
Why?
| | Port-Wine Stain | 1 | 2013 | 2 | 0.100 |
Why?
| | Delivery Rooms | 1 | 2013 | 7 | 0.100 |
Why?
| | Liver Function Tests | 1 | 2013 | 114 | 0.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2022 | 804 | 0.100 |
Why?
| | Pediatrics | 2 | 2011 | 1112 | 0.100 |
Why?
| | Administration, Topical | 1 | 2013 | 148 | 0.100 |
Why?
| | Equipment Failure | 1 | 2013 | 108 | 0.100 |
Why?
| | Lung | 1 | 2005 | 4065 | 0.100 |
Why?
| | Intubation | 1 | 2012 | 3 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2013 | 430 | 0.100 |
Why?
| | Health Care Surveys | 2 | 2011 | 563 | 0.100 |
Why?
| | Respiration | 1 | 2013 | 197 | 0.100 |
Why?
| | Pentobarbital | 1 | 2011 | 16 | 0.090 |
Why?
| | Survival Rate | 2 | 2013 | 1969 | 0.090 |
Why?
| | Australia | 1 | 2013 | 314 | 0.090 |
Why?
| | Patient Admission | 1 | 2013 | 191 | 0.090 |
Why?
| | Adult | 12 | 2024 | 37616 | 0.090 |
Why?
| | Vein of Galen Malformations | 1 | 2011 | 2 | 0.090 |
Why?
| | Down Syndrome | 1 | 2018 | 490 | 0.090 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2011 | 22 | 0.090 |
Why?
| | Status Epilepticus | 1 | 2011 | 50 | 0.090 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 24 | 0.090 |
Why?
| | Heterocyclic Compounds | 1 | 2011 | 20 | 0.090 |
Why?
| | Middle Aged | 11 | 2024 | 33200 | 0.090 |
Why?
| | Airway Obstruction | 1 | 2013 | 162 | 0.090 |
Why?
| | Professional Practice | 1 | 2011 | 64 | 0.090 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 596 | 0.090 |
Why?
| | Receptors, CXCR4 | 1 | 2011 | 85 | 0.090 |
Why?
| | Linear Models | 1 | 2013 | 845 | 0.090 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2011 | 50 | 0.090 |
Why?
| | Chemoprevention | 1 | 2011 | 92 | 0.090 |
Why?
| | Nutritional Support | 1 | 2010 | 34 | 0.090 |
Why?
| | Anesthetics, Intravenous | 1 | 2010 | 47 | 0.090 |
Why?
| | Ventilator Weaning | 1 | 2010 | 36 | 0.090 |
Why?
| | Diet, Fat-Restricted | 1 | 2010 | 79 | 0.080 |
Why?
| | Electrocardiography | 1 | 2013 | 628 | 0.080 |
Why?
| | ROC Curve | 1 | 2012 | 545 | 0.080 |
Why?
| | Fatal Outcome | 1 | 2011 | 304 | 0.080 |
Why?
| | Salvage Therapy | 1 | 2011 | 142 | 0.080 |
Why?
| | Aortic Coarctation | 1 | 2011 | 83 | 0.080 |
Why?
| | Propofol | 1 | 2010 | 73 | 0.080 |
Why?
| | Infusions, Intravenous | 3 | 2018 | 408 | 0.080 |
Why?
| | Analgesics, Opioid | 1 | 2018 | 991 | 0.080 |
Why?
| | Drainage | 1 | 2010 | 168 | 0.080 |
Why?
| | Kinetics | 1 | 2013 | 1668 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 413 | 0.080 |
Why?
| | Lymphoma | 1 | 2011 | 206 | 0.080 |
Why?
| | Hypnotics and Sedatives | 1 | 2011 | 199 | 0.080 |
Why?
| | Birth Weight | 1 | 2013 | 514 | 0.080 |
Why?
| | Maximum Tolerated Dose | 3 | 2015 | 198 | 0.080 |
Why?
| | Device Removal | 1 | 2010 | 138 | 0.080 |
Why?
| | Plasmapheresis | 1 | 2008 | 24 | 0.080 |
Why?
| | Alprostadil | 1 | 2008 | 32 | 0.080 |
Why?
| | High-Frequency Ventilation | 1 | 2008 | 45 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1483 | 0.070 |
Why?
| | Vincristine | 3 | 2015 | 116 | 0.070 |
Why?
| | Renal Replacement Therapy | 1 | 2008 | 92 | 0.070 |
Why?
| | Kidney | 1 | 2016 | 1463 | 0.070 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2014 | 1055 | 0.070 |
Why?
| | Neoadjuvant Therapy | 1 | 2010 | 403 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2015 | 891 | 0.070 |
Why?
| | Adolescent | 8 | 2018 | 21463 | 0.070 |
Why?
| | Doxorubicin | 3 | 2015 | 365 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2030 | 0.060 |
Why?
| | Patient Readmission | 1 | 2012 | 695 | 0.060 |
Why?
| | Immunologic Factors | 1 | 2008 | 237 | 0.060 |
Why?
| | Preoperative Care | 1 | 2008 | 356 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2010 | 778 | 0.060 |
Why?
| | Anticoagulants | 1 | 2011 | 658 | 0.060 |
Why?
| | Interferons | 1 | 2007 | 199 | 0.060 |
Why?
| | rho-Associated Kinases | 1 | 2005 | 83 | 0.060 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 551 | 0.060 |
Why?
| | HIV Infections | 1 | 2019 | 2812 | 0.060 |
Why?
| | Hemorrhage | 1 | 2008 | 723 | 0.050 |
Why?
| | Antineoplastic Agents | 2 | 2022 | 2129 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 890 | 0.050 |
Why?
| | Attitude of Health Personnel | 1 | 2011 | 1157 | 0.050 |
Why?
| | Prednisone | 2 | 2015 | 243 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2005 | 455 | 0.050 |
Why?
| | Autografts | 1 | 2022 | 44 | 0.050 |
Why?
| | Melphalan | 1 | 2022 | 35 | 0.050 |
Why?
| | Thrombocytopenia | 2 | 2015 | 199 | 0.050 |
Why?
| | Pneumonia | 2 | 2020 | 638 | 0.050 |
Why?
| | Lung Diseases | 1 | 2008 | 768 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2019 | 3537 | 0.040 |
Why?
| | Recurrence | 2 | 2015 | 1058 | 0.040 |
Why?
| | Severity of Illness Index | 1 | 2008 | 2831 | 0.040 |
Why?
| | Viscera | 1 | 2020 | 17 | 0.040 |
Why?
| | Immunoglobulin Light Chains | 1 | 2020 | 47 | 0.040 |
Why?
| | Cellulitis | 1 | 2020 | 53 | 0.040 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2020 | 83 | 0.040 |
Why?
| | Nervous System | 1 | 2020 | 67 | 0.040 |
Why?
| | South Africa | 1 | 2019 | 219 | 0.040 |
Why?
| | Heart Failure | 1 | 2012 | 2228 | 0.040 |
Why?
| | Cardiopulmonary Bypass | 1 | 2020 | 209 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2020 | 7569 | 0.040 |
Why?
| | Postoperative Period | 1 | 2018 | 343 | 0.030 |
Why?
| | Thrombelastography | 1 | 2018 | 153 | 0.030 |
Why?
| | Anti-Retroviral Agents | 1 | 2019 | 232 | 0.030 |
Why?
| | Infant Mortality | 1 | 2018 | 115 | 0.030 |
Why?
| | Rats | 1 | 2005 | 5628 | 0.030 |
Why?
| | Specimen Handling | 1 | 2017 | 178 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1611 | 0.030 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 350 | 0.030 |
Why?
| | Ultrasonography | 1 | 2019 | 751 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2750 | 0.030 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2015 | 128 | 0.030 |
Why?
| | Hydroxamic Acids | 1 | 2014 | 89 | 0.030 |
Why?
| | Oligopeptides | 1 | 2015 | 272 | 0.030 |
Why?
| | Hyperbilirubinemia | 1 | 2013 | 13 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2015 | 209 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 2015 | 220 | 0.030 |
Why?
| | Liver Failure | 1 | 2013 | 94 | 0.020 |
Why?
| | Neutropenia | 1 | 2013 | 146 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 808 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2847 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2011 | 29 | 0.020 |
Why?
| | Ventricular Function, Right | 1 | 2014 | 283 | 0.020 |
Why?
| | Neural Conduction | 1 | 2012 | 86 | 0.020 |
Why?
| | Cytarabine | 1 | 2011 | 61 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2011 | 113 | 0.020 |
Why?
| | Multiple Organ Failure | 1 | 2012 | 127 | 0.020 |
Why?
| | Benzylamines | 1 | 2011 | 41 | 0.020 |
Why?
| | Prostaglandins | 1 | 2011 | 97 | 0.020 |
Why?
| | Indoles | 1 | 2014 | 410 | 0.020 |
Why?
| | Survival Analysis | 1 | 2014 | 1319 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2011 | 88 | 0.020 |
Why?
| | Mouth | 1 | 2011 | 86 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2011 | 74 | 0.020 |
Why?
| | Blood Component Removal | 1 | 2011 | 26 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3429 | 0.020 |
Why?
| | Internationality | 1 | 2011 | 155 | 0.020 |
Why?
| | Liver Cirrhosis | 1 | 2013 | 316 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2014 | 1981 | 0.020 |
Why?
| | Electroencephalography | 1 | 2011 | 433 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2011 | 584 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 400 | 0.020 |
Why?
| | Animals | 2 | 2010 | 36768 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2012 | 900 | 0.020 |
Why?
| | Internet | 1 | 2011 | 648 | 0.020 |
Why?
| | Young Adult | 2 | 2011 | 13126 | 0.010 |
Why?
| | Liver | 1 | 2013 | 1938 | 0.010 |
Why?
| | Immunotherapy | 1 | 2007 | 640 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2007 | 1455 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 5744 | 0.010 |
Why?
| | United States | 1 | 2011 | 14660 | 0.010 |
Why?
| | Mice | 1 | 2010 | 17731 | 0.010 |
Why?
|
|
Kaufman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|